ASL
Basic information
Region (hg38): 7:66075800-66094697
Links
Phenotypes
GenCC
Source:
- argininosuccinic aciduria (Definitive), mode of inheritance: AR
- argininosuccinic aciduria (Definitive), mode of inheritance: AR
- argininosuccinic aciduria (Strong), mode of inheritance: AR
- argininosuccinic aciduria (Definitive), mode of inheritance: AR
- argininosuccinic aciduria (Supportive), mode of inheritance: AR
- argininosuccinic aciduria (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Argininosuccinic aciduria | AR | Biochemical; Pharmacogenomic | Dietary and medical therapy (eg, with low-protein diet supplemented with arginine), may be beneficial, and special care to prevent/treat acute metabolic decompensation (eg, with IV glucose and ammonia-reducing agents) may be effective; Certain agents (such as enflurane, an anesthetic agent) should be avoided due to reports of adverse reactions | Biochemical; Dermatologic; Neurologic | 13503250; 5836520; 84150; 2263616; 1897577; 1594374; 9504797; 12408190; 12384776; 17326097; 22541557; 20236848; 19635676; 22541557; 22841516; 23040521; 25135652 |
ClinVar
This is a list of variants' phenotypes submitted to
- Argininosuccinate lyase deficiency (63 variants)
- not provided (11 variants)
- ASL-related disorder (3 variants)
- Congenital myasthenic syndrome 4C (1 variants)
- Neurodevelopmental disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ASL gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 213 | 217 | ||||
missense | 20 | 74 | 91 | 193 | ||
nonsense | 14 | 16 | 30 | |||
start loss | 0 | |||||
frameshift | 16 | 28 | 44 | |||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 13 | 28 | 42 | |||
splice region | 1 | 15 | 62 | 1 | 79 | |
non coding | 153 | 35 | 195 | |||
Total | 64 | 146 | 101 | 374 | 38 |
Highest pathogenic variant AF is 0.000341
Variants in ASL
This is a list of pathogenic ClinVar variants found in the ASL region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
7-66075865-G-A | Argininosuccinate lyase deficiency • not specified | Conflicting classifications of pathogenicity (Jan 12, 2018) | ||
7-66075866-C-T | not specified | Likely benign (Mar 14, 2016) | ||
7-66076048-A-G | Argininosuccinate lyase deficiency | Uncertain significance (Apr 27, 2017) | ||
7-66076051-G-A | Argininosuccinate lyase deficiency • not specified | Conflicting classifications of pathogenicity (Jan 13, 2018) | ||
7-66076066-C-T | Argininosuccinate lyase deficiency | Uncertain significance (Jan 12, 2018) | ||
7-66076086-C-A | Argininosuccinate lyase deficiency • Inborn genetic diseases | Uncertain significance (Dec 11, 2023) | ||
7-66076089-C-CG | Argininosuccinate lyase deficiency | Likely pathogenic (Feb 01, 2024) | ||
7-66076101-G-A | Argininosuccinate lyase deficiency | Likely benign (Jul 13, 2022) | ||
7-66076103-A-T | Argininosuccinate lyase deficiency | Likely benign (Dec 19, 2023) | ||
7-66076104-C-A | Argininosuccinate lyase deficiency | Likely benign (Jan 30, 2024) | ||
7-66076107-C-T | Argininosuccinate lyase deficiency | Likely benign (Dec 26, 2023) | ||
7-66076108-G-T | Argininosuccinate lyase deficiency | Likely benign (Apr 28, 2023) | ||
7-66076110-G-A | Argininosuccinate lyase deficiency | Likely benign (Jul 08, 2023) | ||
7-66076113-C-A | Argininosuccinate lyase deficiency | Likely benign (Apr 07, 2023) | ||
7-66076198-C-T | Argininosuccinate lyase deficiency | Benign (Jul 01, 2021) | ||
7-66076320-C-G | Benign (Jun 14, 2018) | |||
7-66081579-CA-C | Likely benign (Oct 20, 2019) | |||
7-66081784-T-C | Argininosuccinate lyase deficiency | Likely benign (Jan 22, 2022) | ||
7-66081789-G-T | Argininosuccinate lyase deficiency | Likely benign (Feb 18, 2023) | ||
7-66081791-T-A | Argininosuccinate lyase deficiency | Likely benign (Apr 28, 2023) | ||
7-66081793-T-C | Argininosuccinate lyase deficiency | Likely benign (Dec 15, 2020) | ||
7-66081795-C-T | Argininosuccinate lyase deficiency | Likely benign (Dec 18, 2023) | ||
7-66081796-T-C | Argininosuccinate lyase deficiency | Likely benign (May 17, 2023) | ||
7-66081799-C-T | Argininosuccinate lyase deficiency | Likely benign (Jan 28, 2024) | ||
7-66081801-A-G | Argininosuccinate lyase deficiency | Likely pathogenic (Dec 31, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ASL | protein_coding | protein_coding | ENST00000304874 | 16 | 17761 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
8.57e-10 | 0.899 | 125678 | 0 | 66 | 125744 | 0.000262 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.749 | 247 | 282 | 0.875 | 0.0000195 | 3011 |
Missense in Polyphen | 78 | 107.79 | 0.72365 | 1152 | ||
Synonymous | -1.37 | 134 | 115 | 1.16 | 0.00000822 | 908 |
Loss of Function | 1.83 | 19 | 29.8 | 0.638 | 0.00000168 | 303 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000150 | 0.000150 |
Ashkenazi Jewish | 0.000199 | 0.000198 |
East Asian | 0.000383 | 0.000381 |
Finnish | 0.000200 | 0.000185 |
European (Non-Finnish) | 0.000360 | 0.000352 |
Middle Eastern | 0.000383 | 0.000381 |
South Asian | 0.000263 | 0.000261 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Disease
- DISEASE: Argininosuccinic aciduria (ARGINSA) [MIM:207900]: An autosomal recessive disorder of the urea cycle. The disease is characterized by mental and physical retardation, liver enlargement, skin lesions, dry and brittle hair showing trichorrhexis nodosa microscopically and fluorescing red, convulsions, and episodic unconsciousness. {ECO:0000269|PubMed:12408190, ECO:0000269|PubMed:1705937, ECO:0000269|PubMed:17326097, ECO:0000269|PubMed:19703900, ECO:0000269|PubMed:2263616, ECO:0000269|PubMed:24166829}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Alanine, aspartate and glutamate metabolism - Homo sapiens (human);Arginine biosynthesis - Homo sapiens (human);Argininemia;Hyperornithinemia with gyrate atrophy (HOGA);Creatine deficiency, guanidinoacetate methyltransferase deficiency;L-arginine:glycine amidinotransferase deficiency;Hyperornithinemia-hyperammonemia-homocitrullinuria [HHH-syndrome];Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency);Citrullinemia Type I;Carbamoyl Phosphate Synthetase Deficiency;Argininosuccinic Aciduria;Hypoacetylaspartia;Urea Cycle;Aspartate Metabolism;Prolinemia Type II;Prolidase Deficiency (PD);Ornithine Transcarbamylase Deficiency (OTC Deficiency);Arginine and Proline Metabolism;Hyperprolinemia Type I;Hyperprolinemia Type II;Ornithine Aminotransferase Deficiency (OAT Deficiency);Arginine: Glycine Amidinotransferase Deficiency (AGAT Deficiency);Canavan Disease;Alanine and aspartate metabolism;Urea cycle and metabolism of amino groups;Citrate cycle;Alanine Aspartate Asparagine metabolism;Metabolism of polyamines;Metabolism of amino acids and derivatives;Metabolism;citrulline-nitric oxide cycle;urea cycle;Arginine Proline metabolism;Urea cycle
(Consensus)
Recessive Scores
- pRec
- 0.454
Intolerance Scores
- loftool
- 0.0497
- rvis_EVS
- -0.98
- rvis_percentile_EVS
- 8.85
Haploinsufficiency Scores
- pHI
- 0.0865
- hipred
- N
- hipred_score
- 0.112
- ghis
- 0.460
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.964
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Asl
- Phenotype
- endocrine/exocrine gland phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); muscle phenotype; renal/urinary system phenotype; immune system phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype;
Gene ontology
- Biological process
- urea cycle;locomotory behavior;post-embryonic development;ammonia assimilation cycle;arginine biosynthetic process via ornithine
- Cellular component
- cytoplasm;cytosol;extracellular exosome
- Molecular function
- argininosuccinate lyase activity;protein binding;identical protein binding